Sutro Biopharma Net Worth
Sutro Biopharma Net Worth Breakdown | STRO |
Sutro Biopharma Net Worth Analysis
Sutro Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sutro Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sutro Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sutro Biopharma's net worth analysis. One common approach is to calculate Sutro Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sutro Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sutro Biopharma's net worth. This approach calculates the present value of Sutro Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sutro Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sutro Biopharma's net worth. This involves comparing Sutro Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sutro Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Sutro Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sutro Biopharma's net worth research are outlined below:
| Sutro Biopharma generated a negative expected return over the last 90 days | |
| Sutro Biopharma has high historical volatility and very poor performance | |
| Sutro Biopharma has some characteristics of a very speculative penny stock | |
| Sutro Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 62.04 M. Net Loss for the year was (227.46 M) with profit before overhead, payroll, taxes, and interest of 49.54 M. | |
| Sutro Biopharma currently holds about 225.64 M in cash with (191.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Sutro Biopharma lays off dozens of employees in strategic portfolio review - Yahoo News |
Sutro Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sutro Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sutro Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Sutro Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sutro Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sutro Biopharma backward and forwards among themselves. Sutro Biopharma's institutional investor refers to the entity that pools money to purchase Sutro Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.9 M | Parkman Healthcare Partners Llc | 2024-12-31 | 1.7 M | Goldman Sachs Group Inc | 2024-12-31 | 1.7 M | State Street Corp | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.5 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.1 M | Renaissance Technologies Corp | 2024-12-31 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 859.4 K | Blackrock Inc | 2024-12-31 | 7.6 M | Suvretta Capital Management, Llc | 2024-12-31 | 7.5 M |
Follow Sutro Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 75.07 M.Market Cap |
|
Project Sutro Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.93) | (0.89) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (5.10) | (4.84) |
When accessing Sutro Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sutro Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sutro Biopharma's profitability and make more informed investment decisions.
Evaluate Sutro Biopharma's management efficiency
Sutro Biopharma has return on total asset (ROA) of (0.3474) % which means that it has lost $0.3474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.3419) %, meaning that it created substantial loss on money invested by shareholders. Sutro Biopharma's management efficiency ratios could be used to measure how well Sutro Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of March 2025, Return On Tangible Assets is likely to drop to -0.62. In addition to that, Return On Capital Employed is likely to grow to -0.89. At this time, Sutro Biopharma's Non Current Assets Total are very stable compared to the past year. As of the 19th of March 2025, Other Current Assets is likely to grow to about 18.7 M, while Total Assets are likely to drop about 304.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.58 | 0.55 | |
| Tangible Book Value Per Share | 0.58 | 0.55 | |
| Enterprise Value Over EBITDA | 0.14 | 0.14 | |
| Price Book Value Ratio | 3.17 | 3.33 | |
| Enterprise Value Multiple | 0.14 | 0.14 | |
| Price Fair Value | 3.17 | 3.33 | |
| Enterprise Value | -25.8 M | -24.5 M |
The strategic initiatives led by Sutro Biopharma's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.3577 | Revenue | Quarterly Revenue Growth (0.87) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sutro Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sutro Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sutro Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sutro Biopharma time-series forecasting models is one of many Sutro Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sutro Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Sutro Biopharma Earnings per Share Projection vs Actual
Sutro Biopharma Corporate Management
| Barbara Leyman | Chief Officer | Profile | |
| Shabbir Anik | Chief Technical Operations Officer | Profile | |
| William JD | CEO Director | Profile | |
| Nicki Vasquez | Chief Officer | Profile | |
| Annie MBA | VP Relations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth (0.87) | Return On Assets | Return On Equity |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.